Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (36)

2024

  1. Circulating immunome fingerprint in eosinophilic esophagitis is associated with clinical response to proton pump inhibitor treatment

    Frontiers in Immunology, Vol. 15

  2. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

2023

  1. Expression of HMGCS2 in intestinal epithelial cells is downregulated in inflammatory bowel disease associated with endoplasmic reticulum stress

    Frontiers in immunology, Vol. 14, pp. 1185517

  2. Genetic reanalysis of patients with a difference of sex development carrying the NR5A1/SF-1 variant p.Gly146Ala has discovered other likely disease-causing variations

    PloS one, Vol. 18, Núm. 7, pp. e0287515

2022

  1. Metabolomics study of COVID-19 patients in four different clinical stages

    Scientific reports, Vol. 12, Núm. 1, pp. 1650

2021

  1. Esophageal microbiome in active eosinophilic esophagitis and changes induced by different therapies

    Scientific Reports, Vol. 11, Núm. 1

  2. Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract

    Molecular Nutrition and Food Research, Vol. 65, Núm. 12

  3. Management of Helicobacter pylori infection in the pediatric age

    Anales de Pediatria, Vol. 95, Núm. 5, pp. 383.e1-383.e9

2020

  1. A quick flow cytometry protocol to assess Helicobacter pylori viability

    Journal of Microbiological Methods, Vol. 177

  2. Serum adipokines as non-invasive biomarkers in Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  3. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  3. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854

  4. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  5. Effectiveness and safety of the switch from remicade® to CT-P13 in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 13, Núm. 11, pp. 1380-1386

  6. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

  7. Immunomodulatory effect of gut microbiota-derived bioactive peptides on human immune system from healthy controls and patients with inflammatory bowel disease

    Nutrients, Vol. 11, Núm. 11

  8. Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity

    Immunity, Vol. 50, Núm. 2, pp. 446-461.e9

  9. Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract

    Journal of Functional Foods, Vol. 52, pp. 459-468